Skip to navigation Skip to content

Chronic spontaneous urticaria (CSU) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051109

This document outlines details of PBS-subsidised omalizumab for patients with severe chronic spontaneous urticaria (CSU).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

On this page:

CSU quick reference

Delayed assessment

CSU quick reference

Table 1

Restrictions

Authority Level and section

PA assessment

Processing system

Prescriber type

Prescriber self-service

Initial

or

Re-initiation

PB223 form

Written

Electronic

S100:

omalizumab

(Any patient who ceases therapy and relapses will need to re-initiate as a new patient)

No

OPA

Must be treated by:

a clinical immunologist
an allergist
a dermatologist
a general physician with expertise in managing CSU

Yes - immediate or delayed assessment (delayed if any free text option used)

Continuing

Telephone

Electronic

S100:

omalizumab

No

OPA

Must be treated by:

a clinical immunologist
an allergist
a dermatologist
a general physician with expertise in managing CSU

Yes

Delayed assessment

Delayed assessment due to:

contraindication and/or intolerance to prior therapies
patient taking a drug not specified in the listed options

Table 2: this table lists the details of what to check for the delayed assessment and common acronyms.

Service Officers to assess that free text is:	Examples	Outcome
Relevant to the question	A drug name Heart condition Worsened renal failure Nausea and vomiting Elevated or deranged etc. liver function test Gastrointestinal toxicity	Approve
Random text	Happy Birthday Patient did not want to take Ikasditbn	Reject
Non-descriptive	Grade 3 (no detail of toxicity) Toxicity	Reject

Common acronyms

LFT - Liver function tests
GI toxicity - Gastrointestinal
N+V - Nausea and vomiting

Escalate to a Pharmaceutical Adviser (PA) by phone if unsure of the acronym used.